Gland Pharma Share Price Jumps 12% to 4-Year High

Gland Pharma shares rose 12% on Tuesday to reach a four-year high of ₹2,989.25 on the BSE, driven by strong financial results for the June 2026 quarter. The stock gained despite a weak broader market, reaching its highest level since May 2022.

Over the past four trading sessions, the stock has gained 17%. From its 52-week low of ₹1,575 recorded on March 16, 2026, the stock has recovered nearly 90%. Its all-time high remains ₹4,350, touched in August 2021.

Gland Pharma reported a better-than-expected performance for Q1FY27, with consolidated profit after tax rising 47% year-on-year to ₹317 crore compared with ₹215.5 crore in the same quarter last year. Revenue from operations increased 19.6% year-on-year to ₹1,800 crore.

Earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 33% to ₹489 crore, while EBITDA margin improved by 276 basis points to 27.2%. The company’s growth was supported by strong performance in the US and European Union markets.

However, some of its other key markets and the rest-of-world segment remained subdued. The company has announced capital expenditure of more than ₹2,000 crore over the next five years to expand capacity, as existing facilities are operating at 80-90% utilisation.

Gland Pharma’s management aims to achieve annual growth of 18-20% over the next three to four years, driven by complex molecules and new business opportunities. Analysts expect recent agreements, including a sterile API partnership with Neuland and a contract development and manufacturing organisation (CDMO) partnership with a global specialty pharmaceutical company, to support future growth.

The company is also expanding its GLP-1 fill-finish capacity. Its current capacity of 40 million cartridges is planned to increase to 140 million. Gland Pharma recently signed another agreement with a global pharmaceutical company under which manufacturing will be carried out at its facility, followed by packaging at Cenexi’s site, creating a full-service CDMO offering.

With improving earnings, capacity expansion and growing CDMO opportunities, analysts expect the company’s long-term outlook to remain positive. The strong Q1 results and expansion plans have boosted investor confidence, leading to the surge in the stock price.

The pharmaceutical sector has been performing well in recent times, driven by strong demand and new business opportunities. Gland Pharma’s focus on complex molecules and CDMO partnerships is expected to drive growth in the coming years.

The company’s expansion plans and growing CDMO opportunities are expected to support future growth. With a strong Q1 performance and a positive outlook, Gland Pharma is well-positioned for long-term growth.

In conclusion, Gland Pharma’s strong Q1 results and expansion plans have driven the stock price to a four-year high. The company’s focus on complex molecules and CDMO partnerships is expected to drive growth in the coming years, making it a promising investment opportunity.